Clarithromycin (Klamer 500 mg) and Maraviroc: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Strong CYP3A inhibition can increase maraviroc exposure.
Clinical significance and safety
Klamer 500 mg can raise maraviroc exposure through strong CYP3A inhibition. The HIV team must review the complete regimen, including any inducer, and product-specific adjustment requirements. The cited U.S. maraviroc label contraindicates this potent-inhibitor combination in severe renal impairment or end-stage renal disease; do not change treatment independently.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.